Fibromyalgia: Pathogenetic, diagnostic and therapeutic concerns

Polskie Archiwum Medycyny Wewnetrznej

Volumn 119, Issue 3, 2009, Pages 157-161

  Podolecki, Tomasz ^a,c   Podolecki, Andrzej ^b   Hrycek, Antoni ^c  

^a Clinical Hospital   (Poland)

^b District Hospital   (Poland)

^c MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Central sensitization; Fibromyalgia; Interleukin; Tender points

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BIOGENIC AMINE; DULOXETINE; GLUCOCORTICOID; HARKOSERIDE; LIDOCAINE; MILNACIPRAN; NONSTEROID ANTIINFLAMMATORY AGENT; PREGABALIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; STEROID; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT;

AMINO ACID BLOOD LEVEL; CENTRAL NERVOUS SYSTEM; CHRONIC FATIGUE SYNDROME; CLINICAL FEATURE; CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DRUG EFFICACY; ELECTROENCEPHALOGRAM; FIBROMYALGIA; HEREDITY; HUMAN; IMMUNOPATHOLOGY; MASSAGE; MYALGIA; PAIN; PREVALENCE; PROTEIN METABOLISM; PSYCHOSOMATIC DISORDER; PSYCHOTHERAPY; QUALITY OF LIFE; REVIEW; SLEEP DISORDER; SPHYGMOMANOMETRY;

EID: 64149122937     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.636     Document Type: Review

References (33)

1. Gilliland B. [Arthritis Associated with Systemic Disease and Other Arthritides]. In: Fauci AS, Braunwald E, Isselbacher KJ, eds. [Harrison's Principles of Internal Medicine]. Wyd. Czelej, Lublin 2000: 3301-3304. Polish.
2. Bliddal H, Danneskiold-Samsoe B. Chronic widespread pain in the spectrum of rheumatological diseases. Best Pract Res Clin Rheumatol. 2007; 21:391-402.
3. Williams DA. Gracely RH. Biology and therapy of fibromyalgia. Functional magnetic resonance imaging findings in fibromyalgia. Arthritis Res Ther. 2006; 8: 224.
4. Katz D, Greene L, Ather A, et al. The pain of fibromyalgia syndrome is due to muscle hypoperfusion induced by regional vasomotor dysregulation. Med Hypotheses. 2007; 89: 517-525.
5. Ozgocmen S, Ozyurt H, Sogut S, et al. Antioxidant status, lipid peroxidation and nitric oxide in fibromyalgia: etiologic and therapeutic concerns. Rheumatol Int. 2006; 26: 598-603.
6. Alvarez L, Valdivielso A, Lopez A, et al. Fibromyalgia syndrome: overnight falls in arterial oxygen saturation. Am J Med. 1996; 101: 54-60.
7. Maes M, Verkerk R, Delmeire L, et al. Serotonergic markers and lowered plasma branched-chain-amino acid concentrations in fibromyalgia. Psychiatry Res. 2000; 97: 11-20.
8. Bigatti SM, Hernandez AM, Cronan TA, et al. Sleep disturbances in fibromyalgia syndrome: relationship to pain and depression. Arthritis Rheum. 2008; 59:961-967.
9. Bazzichi L, Rossi A, Massimetti G, et al. Cytokine patterns in fibromyalgia and their correlation with clinical manifestations. Clin Exp Rheumatol. 2007; 25: 225-230.
10. Wallace DJ, Linker-Israeli M, Hallegua D, et al. Cytokines piay an aetiopathogenetic role in fibromyalgia: a hypothesis and pilot study. Baillieres Clin Rheumatol. 2001; 40: 743-749.
11. Pongratz DE, Sievers M. Fibromyalgia-symptom or diagnosis: a definition of the position. Scand J Rheumatol Suppl. 2000; 113: 3-7.
12. Gursoy S, Erdal E, Sezgin M, et al. Which genotype of MAO gene that the patients have are likely to be most susceptible to the symptoms of fibromyalgia? Rheumatol Int. 2008; 28: 307-311.
13. Giesecke T, Williams D, Harris R, et al. Subgrouping of fibromyalgia patients on the basis of pressure-pain thresholds and psychological factors. Arthritis Rheum. 2003; 48: 2916-2922.
14. Osorio CD, Gallinaro AL, Lorenzi-Filho G, et ai. Sleep quality in patients with fibromyalgia using PSQI. J Rheumatol. 2006, 33:1863-1865.
15. Staud R, Rodriguez ME. Mechanisms of disease: pain in fibromyalgia syndrome. Nat Clin Pract Rheumatol. 2006; 2: 90-98,
16. Atarowska M, Samborski W. [Difficulties with diagnosis of fibromyalgia: a case report]. Ann Acad Med Stetin. 2006; 52 (Suppl. 2): 105-110. Polish.
17. Harden RN, Revivo G, Song S, et al. A critical analysis of the tender points in fibromyalgia. Pain Med. 2007; 8:147 156.
18. Vargas A, Vargas A, Hernandez-Paz R, et al. Sphygmomanometry-evoked allodynia - a simple bedside test indicative of fibromyalgia: a multicenter developmental study. J Clin Rheumatol. 2006; 12: 272-274.
19. Cacace E, Ruggiero V, Anedda C, et al. [Quality of life and associated clinical distress in fibromyalgia]. Reumatismo. 2006; 58; 226-229. Italian.
20. Theadom A, Cropley M, Humphrey KL. Exploring the role of sleep and coping in quality of life in fibromyalgia. J Psychosom Res. 2007; 62: 145-151.
21. Denko CW, Malemud CJ. Serum growth hormone and insulin hut not insulin-like growth factor-1 levels are elevated in patients with fibromyalgia syndrome. Rheumatol Int. 2005; 25:146-151.
22. Samborski W, Sobieska M, Piȩta P, et al. Normal profile of sex hormones in women with primary fibromyalgia. Ann Acad Med Stetin. 2005; 51:23-26.
23. Michielsen HJ, Van Hoedenhove B, Leirs I, et al. Depression, attribution style and self-esteem in chronic fatigue syndrome and fibromyalgia pa tients: is there a link? Clin Rheumatol. 2006; 25:183-188.
24. Hwang E, Barkhuizen A. Update on rheumatologic mimics of fibromyalgia. Curr Pain Headache Rep. 2006; 10: 327-332.
25. Polańska B. Fibromyalgia syndrome: pathogenesis and diagnostic-therapeutic problems. Pol Merk Lek. 2004; 16: 93-96.
26. Zimmermann-Górska I. Polymyalgia rheumatica: clinical picture and principles of treatment. Pol Arch Med Wewn. 2008; 118: 1-4.
27. Arnold LM. Duloxetine and other antidepressants in the treatment of patients with fibromyalgia. Pain Med. 2007; 2: S63-S74.
28. Arnold LM, Goldenberg DL, Stanford SB, et al. Gabapentin in the treat ment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. Arthritis Rheum. 2007; 56: 1336-1344.
29. Abeles M, Solitar BM, Pillinger MH, et al. Update on fibromyalgia therapy. Am J Med. 2008; 121: 555-561.
30. Staud R. Are tender point injections beneficial: the role of tonic nociception in fibromyalgia. Curr Pharm Des. 2006; 12: 23-27.
31. Thieme K, Turk DC, Flor H. Responder criteria for operant and cognitive-behavioral treatment of fibromyalgia syndrome. Arthritis Rheum. 2007; 57: 830-836.
32. Carville SF, Arendt-Nielsen S, Bliddal H, et al. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis. 2008;67:536-541.
33. Beyreuther BK, Freitag J, Heers C, et al. Lacosamide: a review of preclinical properties. CNS Drug Rev. 2007; 13: 21-42.